News & Events
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
Crinetics Pharmaceuticals ($CRNX) announced today that Rogério Vivaldi Coelho, M. D. , M.
READ MORECrinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
Crinetics Pharmaceuticals ($CRNX) announced today that company management will participate in a fireside chat and one-on-one investor meetings at the Annual Evercore ISI HealthCONx Conference.
READ MORECrinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
Crinetics Pharmaceuticals ($CRNX) announced today that new data from ACROBAT Advance, the ongoing open label extension (OLE) trial of paltusotine in patients with acromegaly, will be featured in a poster presentation at the annual Society for Endocrinology BES congress in Edinburgh, Scotland.
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
We also continue to make strong progress in our efforts to develop paltusotine as an oral treatment for acromegaly and neuroendocrine tumors complicated by carcinoid syndrome. With a strong financial foundation that was recently bolstered by our successful common stock offering, we believe we are well positioned to advance our pipeline programs and achieve a regular cadence of milestones.
READ MORECrinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock
Crinetics Pharmaceuticals ($CRNX) has closed its previously announced underwritten public offering of 8,712,400 shares of its common stock, including 1,136,400 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $19. 80 per share.
READ MORECrinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894, CRN04777 and its other research and development programs, and for working capital and general corporate purposes. SVB Leerink, Evercore ISI and Cantor are acting as joint bookrunning managers for the offering. H.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
